Linda M. Griffith

发表

Transplantation outcomes for severe combined immunodeficiency, 2000-2009.

L. Notarangelo, J. Puck, K. Sullivan, 2014, The New England journal of medicine.

The diagnosis of severe combined immunodeficiency (SCID): The Primary Immune Deficiency Treatment Consortium (PIDTC) 2022 Definitions

L. Notarangelo, J. Puck, S. Pai, 2022, The Journal of allergy and clinical immunology.

Primary Immune Deficiency Treatment Consortium (PIDTC) update.

L. Notarangelo, J. Puck, T. Torgerson, 2016, The Journal of allergy and clinical immunology.

Primary Immune Deficiency Treatment Consortium (PIDTC) report.

M. van der Burg, L. Notarangelo, H. Bobby Gaspar, 2014, The Journal of allergy and clinical immunology.

Measuring the effect of newborn screening on survival after haematopoietic cell transplantation for severe combined immunodeficiency: a 36-year longitudinal study from the Primary Immune Deficiency Treatment Consortium

L. Notarangelo, J. Puck, T. Torgerson, 2023, The Lancet.

The diagnosis of severe combined immunodeficiency: Implementation of the PIDTC 2022 Definitions

L. Notarangelo, J. Puck, K. Sullivan, 2022, The Journal of allergy and clinical immunology.

Poor T-cell receptor β repertoire diversity early posttransplant for severe combined immunodeficiency predicts failure of immune reconstitution

L. Notarangelo, J. Puck, S. S. De Ravin, 2021, The Journal of allergy and clinical immunology.

Infections in Infants with SCID: Isolation, Infection Screening, and Prophylaxis in PIDTC Centers

L. Notarangelo, J. Puck, T. Torgerson, 2020, Journal of Clinical Immunology.

Excellent Outcomes Following Hematopoietic Cell Transplantation for Wiskott-Aldrich Syndrome: A PIDTC Report.

L. Notarangelo, H. Ochs, J. Puck, 2020, Blood.

SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery.

L. Notarangelo, J. Puck, K. Sullivan, 2018, Blood.

B-cell differentiation and IL-21 response in IL2RG/JAK3 SCID patients after hematopoietic stem cell transplantation.

L. Notarangelo, J. Walter, J. Puck, 2018, Blood.

Immune reconstitution and survival of 100 SCID patients post-hematopoietic cell transplant: a PIDTC natural history study.

L. Notarangelo, J. Puck, K. Sullivan, 2017, Blood.

Recommendations for Screening and Management of Late Effects in Patients with Severe Combined Immunodeficiency after Allogenic Hematopoietic Cell Transplantation: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Ped

L. Notarangelo, J. Puck, A. Gennery, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Establishing diagnostic criteria for severe combined immunodeficiency disease (SCID), leaky SCID, and Omenn syndrome: the Primary Immune Deficiency Treatment Consortium experience.

L. Notarangelo, J. Puck, S. Pai, 2014, The Journal of allergy and clinical immunology.

The Natural History of Children with Severe Combined Immunodeficiency: Baseline Features of the First Fifty Patients of the Primary Immune Deficiency Treatment Consortium Prospective Study 6901

L. Notarangelo, J. Puck, S. Pai, 2013, Journal of Clinical Immunology.

Allogeneic hematopoietic cell transplantation for primary immune deficiency diseases: current status and critical needs.

L. Notarangelo, J. Puck, K. Sullivan, 2008, The Journal of allergy and clinical immunology.

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report.

D. Miklos, J. Pidala, E. Russek-Cohen, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report.

J. Wingard, J. Gea-Banacloche, S. Paczesny, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Persistence of recipient plasma cells and anti‐donor isohaemagglutinins in patients with delayed donor erythropoiesis after major ABO incompatible non‐myeloablative haematopoietic cell transplantation

J. P. McCoy, R. Srinivasan, J. McCoy, 2005, British journal of haematology.

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report.

Shannon R. McCurdy, R. Jenq, G. Cuvelier, 2021, Transplantation and cellular therapy.

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group Report.

M. Mohty, Stephanie J. Lee, S. Pavletic, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

T cell repertoire following autologous stem cell transplantation for multiple sclerosis.

C. Desmarais, H. Robins, L. Turka, 2014, The Journal of clinical investigation.

Chronic Graft-versus-Host Disease--implementation of the National Institutes of Health Consensus Criteria for Clinical Trials.

Stephanie J. Lee, S. Pavletic, K. Schultz, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Transfusion support for matched sibling allogeneic hematopoietic stem cell transplantation (1993–2010): factors that predict intensity and time to transfusion independence

A. Barrett, D. Stroncek, J. Tisdale, 2018, Transfusion.

Improving cellular therapy for primary immune deficiency diseases: recognition, diagnosis, and management.

L. Notarangelo, H. Ochs, J. Puck, 2009, The Journal of allergy and clinical immunology.

Prior chemotherapy and allograft CD34+ dose impact donor engraftment following nonmyeloablative allogeneic stem cell transplantation in patients with solid tumors.

N. Geller, W. Linehan, R. Srinivasan, 2004, Blood.

Myeloablative Autologous Stem‐Cell Transplantation for Severe Scleroderma

M. Mayes, S. Heimfeld, K. Sullivan, 2018, The New England journal of medicine.

High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS

D. Arnold, G. Kraft, J. Bowen, 2017, Neurology.

Feasibility of allogeneic hematopoietic stem cell transplantation for autoimmune disease: position statement from a National Institute of Allergy and Infectious Diseases and National Cancer Institute-Sponsored International Workshop, Bethesda, MD, March 12 and 13, 2005.

M. Mayes, B. Sandmaier, Roland Martin, 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Chronic Granulomatous Disease-Associated IBD Resolves and Does Not Adversely Impact Survival Following Allogeneic HCT

L. Notarangelo, J. Puck, T. Torgerson, 2019, Journal of Clinical Immunology.

Acute kidney injury in patients with systemic sclerosis participating in hematopoietic cell transplantation trials in the United States.

M. Mayes, K. Sullivan, D. Furst, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Myeloablative Autologous Transplantation of CD34 + Selected Hematopoietic Stem Cells (HSCT) vs Monthly Intravenous Cyclophosphamide (CY) for Severe Scleroderma with Internal Organ Involvement: Outcomes of a Randomized North American Clinical Trial

M. Mayes, K. Sullivan, D. Furst, 2017 .

High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report.

D. Arnold, G. Kraft, J. Bowen, 2015, JAMA neurology.

Intestinal microbiome and metabolome signatures in patients with chronic granulomatous disease.

C. Deming, S. Conlan, J. Segre, 2023, The Journal of allergy and clinical immunology.

Relevance of lymphocyte proliferation to PHA in severe combined immunodeficiency (SCID) and T cell lymphopenia.

J. Puck, T. Torgerson, S. Pai, 2024, Clinical immunology.

Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation.

Jeffrey A. Cohen, H. Atkins, K. Sullivan, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Survey on retransplantation criteria for patients with severe combined immunodeficiency.

L. Notarangelo, E. Haddad, M. Cowan, 2014, The Journal of allergy and clinical immunology.

Early Hematopoietic Cell Transplant (HCT) Outcomes of Children with Severe Combined Immunodeficiency Disease (SCID): The First Seventy Four Patients of the Primary Immune Deficiency Treatment Consortium (PIDTC) Prospective Study 6901

L. Notarangelo, J. Puck, K. Sullivan, 2015 .

Genotype, Oxidase Status, and Preceding Infection or Autoinflammation Do Not Affect Allogeneic HCT Outcomes for CGD.

L. Notarangelo, J. Puck, T. Torgerson, 2023, Blood.

Outcomes Following Treatment for Adenosine Deaminase Deficient Severe Combined Immunodeficiency: A Report from the PIDTC.

L. Notarangelo, J. Puck, T. Torgerson, 2022, Blood.

Treatment of immunodeficiency: long-term outcome and quality of life.

L. Notarangelo, W. Shearer, L. Griffith, 2008, The Journal of allergy and clinical immunology.

Extensive intrathecal T cell renewal following hematopoietic transplantation for multiple sclerosis.

P. Lindau, H. Robins, L. Turka, 2019, JCI insight.

Glycogenosis type II: A juvenile‐specific mutation with an unusual splicing pattern and a shared mutation in African Americans

N. Raben, P. Plotz, J. Becker, 1997, Human mutation.